We offer inexpensive and highly quality custom ADC conjugate services using our combined approach with a variety of payloads, linkers, and conjugation methods. The types of antibodies (macromolecules) of ADC drugs are unlimited, and the types of linkers, connection methods, and toxins (small molecules) are limited. As a core element, the linker-toxin compound has been patented by pharmaceutical companies. The various FDA clinical linker-drug combinations can be classified into the following:
There are different linker-drug combinations in clinical practice, but the peptide method is the mainstream. Peptide can be broken down by proteases, and it enters the cell faster. After killing the cell, it can also kill surrounding cells. Peptide connects auristatin with cysteine and is widely used.
Syntarga's new SpaceLink technology utilizes highly flexible linkers, allowing these linkers to reversibly link payloads to antibodies in a modular manner. This, in turn, enables the selection and optimization of payload and linker payload combinations to generate ADCs with the greatest therapeutic potential for the target. The anti-HER2-dukamycin conjugate demonstrates the proof-of-concept of this emerging technology with antitumor efficacy with minimal off-target toxicity in vivo. This technology may have a wider range of uses and can be universally used in ADC production.
The optimal linker-payload combination cannot be intuitively predicted in ADC development to achieve the most efficient and tolerable ADC for a given goal. Therefore, BOC Sciences can provide you with the linker and toxin connection method you are interested in. We provide the following services:
In addition, BOC Sciences provides the use of radiolabeled linkers and payloads for ADCs, which can use xenograft models to help identify metabolites and free payloads in the circulation. BOC Sciences accepts the customer-designed linker-toxin combination and develops the process to provide a complete service.